Filing Details
- Accession Number:
- 0001552781-16-001977
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-10-05 16:49:48
- Reporting Period:
- 2016-10-03
- Filing Date:
- 2016-10-05
- Accepted Time:
- 2016-10-05 16:49:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1125345 | Macrogenics Inc | MGNX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1587487 | Marc Jon Wigginton | 9704 Medical Center Drive Rockville MD 20850 | Sr Vp, Clinical Dev. & Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-10-03 | 10,000 | $4.70 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-10-03 | 10,000 | $29.34 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2016-10-03 | 10,000 | $0.00 | 10,000 | $4.70 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
15,254 | 2014-01-18 | 2023-07-18 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016.
- This transaction was executed in multiple trades at prices ranging from $28.755 to $29.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.